- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02980341
Phase I/II Study of U3-1402 in Subjects With Human Epidermal Growth Factor Receptor 3 (HER3) Positive Metastatic Breast Cancer
Phase 1/2, Multicenter, Open-label, Multiple-Dose First-in-human Study of U3-1402, in Subjects With HER3 Positive Metastatic Breast Cancer
This is an open-label, three-part, multiple-dose study to evaluate safety, tolerability, and efficacy of U3-1402 in patients with HER3-positive metastatic breast cancer. HER3 is a unique member of the human epidermal growth factor receptor, which defines a certain type of cancer.
The number of patients and treatment cycles are not fixed in this study. Subjects who continue to derive clinical benefit from the study treatment in the absence of withdrawal of consent, progressive disease (PD), unacceptable toxicity, or death may continue the study treatment until the end of the trial.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Chiba, Japan, 277-8577
- National Cancer Center Hospital East
-
Fukushima, Japan, 960-1295
- Fukushima Medical University Hospital
-
Hiroshima, Japan, 730-518
- Local Independent Administrative Corporation Hiroshima City Hospital Organization Hiroshima City Hiroshima Citizens Hospital
-
Kagoshima, Japan, 892-0833
- Hakuaikai Social Medical Corporation Sagara Hospital
-
Kanagawa, Japan, 241-0815
- Kanagawa cancer center
-
Kumamoto, Japan, 860-8556
- Kumamoto University Hospital
-
Nagoya, Japan, 467-8602
- Nagoya City University Hospital
-
Nagoya, Japan, 464-8681
- Aichi Cancer Center Hospital
-
Osaka, Japan, 540-0006
- National Hospital Organization Osaka National Hospital
-
Osaka, Japan, 589-8511
- Kindai University Hospital
-
Osaka, Japan, 541-8567
- Osaka International Cancer Institute
-
Saitama, Japan, 350-1298
- Saitama Medical University International Medical Center
-
Saitama, Japan, 362 0806
- Saitama Cancer Center
-
Tokyo, Japan, 104-0045
- National Cancer Center Hospital
-
Tokyo, Japan, 135-8550
- The Cancer Institute Hospital of Japanese Foundation for Cancer Research
-
-
Hokkaido
-
Sapporo-Shi, Hokkaido, Japan, 003-0804
- National Hospital Organization Hokkaido Cancer Center
-
-
-
-
Georgia
-
Newnan, Georgia, United States, 30265
- Southeastern Regional Medical Center
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Northwestern University
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
Boston, Massachusetts, United States, 02215
- Dana Farber Cancer Institute
-
-
New York
-
Bronx, New York, United States, 10467
- Albert Einstein College of Medicine
-
New York, New York, United States, 10022
- Memorial Sloan Kettering Cancer Center
-
-
Texas
-
Dallas, Texas, United States, 75390
- UT Southwestern Medical Center
-
Dallas, Texas, United States, 75231
- Texas Oncology, P.A.
-
Houston, Texas, United States, 77030
- University of Texas MD Anderson Cancer Center
-
San Antonio, Texas, United States, 78229
- Mays Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Is 18 Years and older in the United States or 20 Years and older in Japan
- Has a pathologically documented advanced/unresectable or metastatic breast cancer
- Documented HER3-positive disease measured by immunohistochemistry (IHC)
- Has disease that is refractory to or intolerable with standard treatment, or for which standard treatment no longer is available
- Has an Eastern Cooperative Oncology Group Performance Status 0-1
- Has Left Ventricular Ejection Fraction ≥ 50%
Has measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
Additional Inclusion Criteria for Dose Finding Part and Dose Expansion Part:
Has received 2-6 prior chemotherapy regimens for breast cancer, at least 2 of which were administered for treatment of advanced/unresectable or metastatic disease. At least 1 prior chemotherapeutic regimen must have included a taxane, administered in the neoadjuvant, adjuvant, or advanced setting. (With exception of Dose Expansion Part TNBC cohort. See additional inclusion criteria for Dose Expansion Part TNBC cohort.)
Additional Inclusion Criteria for Dose Expansion Part Only:
- Is able to submit a fresh tumor biopsy sample prior to starting study treatment if not already submitted for HER3 expression
Has documented hormone (estrogen and/or progesterone) receptor (HR)-positive and HER2 negative expression according to American Society of Clinical Oncology - College of American Pathologists (ASCO-CAP) guidelines. (With exception of Dose Expansion Part TNBC cohort. See additional inclusion criteria for Dose Expansion Part TNBC cohort.)
Additional Inclusion Criteria for Dose Expansion Part TNBC cohort Only:
- Has documented hormone (estrogen and progesterone) receptor (HR)-negative and HER2 negative expression according to American Society of Clinical Oncology - College of American Pathologists (ASCO-CAP) guidelines
- Has progressed after receiving 1 to 2 prior chemotherapy regimens for advanced/unresectable or metastatic breast cancer.
Exclusion Criteria:
- Prior treatment with a HER3 antibody
- Prior treatment with an antibody-drug conjugate (ADC) which consists of an exatecan derivative that is a topoisomerase I inhibitor (eg, DS-8201)
- Has a medical history of symptomatic congestive heart failure (New York Heart Association classes II-IV) or serious cardiac arrhythmia requiring treatment
- Has a medical history of myocardial infarction or unstable angina
- Has a corrected QT prolongation to > 450 millisecond (ms) in males and > 470 ms in females
- Has a medical history of clinically significant lung diseases (eg, interstitial pneumonia, pneumonitis, pulmonary fibrosis, and radiation pneumonitis) or who are suspected to have these diseases by imaging at screening period
Has clinically significant corneal disease
Additional Exclusion Criteria for Dose Expansion Part:
- Prior treatment with an govitecan derivative (eg, IMMU-132).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dose Escalation Part
Participants receive U3-1402 from 1.6 mg/kg to 9.6 mg/kg, administered via intravenous (IV) solution at 3-week intervals.
|
U3-1402 consists of an antibody component (patritumab, U3-1287) covalently conjugated to a drug-linker (MAAA-1162a) containing a drug component (MAAA-1181a)
Other Names:
|
Experimental: Dose Finding Part
Participants receive 1 of 5 different U3-1402 dosing regimens, administered via IV solution at 2 or 3-week intervals at doses at or lower than those studied in the Dose Escalation Part.
|
U3-1402 consists of an antibody component (patritumab, U3-1287) covalently conjugated to a drug-linker (MAAA-1162a) containing a drug component (MAAA-1181a)
Other Names:
|
Experimental: Dose Expansion Part
Participants with HER3 high, HER2 negative, HR positive status receive 4.8 mg/kg or 6.4 mg/kg of U3-1402 administered via intravenous (IV) solution at 3-week intervals.
Participants with HER3 low, HER2 negative, HR positive status receive 6.4 mg/kg of U3-1402 administered via intravenous (IV) solution at 3-week intervals.
Participants with HER3 high, HER2 negative, HR negative status receive 6.4 mg/kg of U3-1402 administration via intravenous (IV) solution at 3-week intervals.
|
U3-1402 consists of an antibody component (patritumab, U3-1287) covalently conjugated to a drug-linker (MAAA-1162a) containing a drug component (MAAA-1181a)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants experiencing adverse events (AEs)
Time Frame: within about 6 months
|
AEs will be collected systematically from signing of the informed consent form (ICF) through 28 days after last dose
|
within about 6 months
|
Number of participants with tumor response throughout the study using Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1
Time Frame: From screening until disease progresses, within about 6 months
|
From screening until disease progresses, within about 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dose Escalation Part: Area under the serum concentration time curve (AUC) of U3-1402
Time Frame: Cycle 1, Day 1 to Cycle 8, Day 1 (148 days)
|
Samples are obtained for all secondary outcome measures in the Dose Escalation Part at Cycle 1: Days 1, 2, 4, 8, 15; Cycle 2: Days 1, 8, 15; Cycle 3: Days 1, 2, 4, 8, 15; Cycles 4, 6, 8: Day 1
|
Cycle 1, Day 1 to Cycle 8, Day 1 (148 days)
|
Dose Finding Part: AUC of U3-1402
Time Frame: Cycle 1, Day 1 to Cycle 8, Day 1 (148 days)
|
Samples are obtained for all secondary outcome measures in the Dose Finding Part for the following categories:
|
Cycle 1, Day 1 to Cycle 8, Day 1 (148 days)
|
Dose Expansion Part: AUC of U3-1402
Time Frame: Cycle 1, Day 1 to Cycle 8, Day 1 (148 days)
|
Samples are obtained for all secondary outcome measures in the Dose Expansion Part at Cycle 1, Days 1, 2, 4, 8, 15; Cycle 2, Day 1; Cycle 3, Days 1, 8, 15; Cycles 4, 6, 8; Day 1
|
Cycle 1, Day 1 to Cycle 8, Day 1 (148 days)
|
Dose Escalation Part: Maximum plasma concentration (Cmax) of U3-1402
Time Frame: within 148 days
|
within 148 days
|
|
Dose Finding Part: Cmax of U3-1402
Time Frame: within 148 days
|
within 148 days
|
|
Dose Expansion Part: Cmax of U3-1402
Time Frame: within 148 days
|
within 148 days
|
|
Dose Escalation Part: Time to maximum plasma concentration (Tmax) of U3-1402
Time Frame: within 148 days
|
within 148 days
|
|
Dose Finding Part: Tmax of U3-1402
Time Frame: within 148 days
|
within 148 days
|
|
Dose Expansion Part: Tmax of U3-1402
Time Frame: within 148 days
|
within 148 days
|
|
Dose Escalation Part: Change in Total anti-HER3 antibody from U3-1402
Time Frame: Baseline, 6 months
|
Baseline, 6 months
|
|
Dose Finding Part: Change in Total anti-HER3 antibody from U3-1402
Time Frame: Baseline, 6 months
|
Baseline, 6 months
|
|
Dose Expansion Part: Change in Total anti-HER3 antibody from U3-1402
Time Frame: Baseline, 6 months
|
Baseline, 6 months
|
|
Dose Escalation Part: Change in MAAA-1181 level from U3-1402
Time Frame: within 148 days
|
within 148 days
|
|
Dose Finding Part: Change in MAAA-1181 level from U3-1402
Time Frame: within 148 days
|
within 148 days
|
|
Dose Expansion Part: Change in MAAA-1181 level from U3-1402
Time Frame: within 148 days
|
within 148 days
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Global Clinical Leader, Daiichi Sankyo, Inc.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- U31402-A-J101
- JapicCTI-163401 (Registry Identifier: JapicCTI)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Breast Cancer
-
Gilead SciencesRecruitingStudy of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors (ASCENT-J02)Advanced Solid Tumor | Metastatic Urothelial Cancer | Metastatic Triple-Negative Breast Cancer | HR+/HER2- Metastatic Breast CancerJapan
-
BriaCell Therapeutics CorporationRecruitingBreast Cancer | Breast Neoplasm | Metastatic Breast Cancer | Breast Cancer Metastatic | End Stage CancerUnited States
-
GlycoMimetics IncorporatedTerminatedBreast Cancer | Breast Cancer Metastatic | HR+ Metastatic Breast CancerUnited States
-
OBI Pharma, IncCompletedMetastatic Colorectal Cancer | Metastatic Lung Cancer | Metastatic Breast Cancer | Metastatic Gastric CancerTaiwan
-
Massachusetts General HospitalPuma Biotechnology, Inc.; Celcuity, Inc.WithdrawnMetastatic Breast Cancer | Invasive Breast Cancer | HER2-negative Breast Cancer | ER Positive Breast Cancer | PR-Positive Breast Cancer | Stage IV (Metastatic) Breast CancerUnited States
-
BriaCell Therapeutics CorporationLumaBridgeEnrolling by invitationBreast Cancer | Breast Neoplasm | Metastatic Breast Cancer | Breast Cancer MetastaticUnited States
-
Institut de Recherches Internationales ServierADIR, a Servier Group companyCompletedMetastatic Breast Cancer | Metastatic Triple Negative Breast CancerJapan, Belgium, France, Netherlands
-
Novartis PharmaceuticalsCompletedMetastatic Breast Cancer | Postmenopausal Women | Locally Advanced Metastatic Breast CancerIsrael
-
Hoffmann-La RocheCompletedHER2-Positive Metastatic Breast Cancer | HER2-Negative Metastatic Breast Cancer | Locally Advanced or Early Breast CancerUnited States
-
Prof. Wolfgang JanniEli Lilly and CompanyRecruitingHormone Receptor-positive Metastatic Breast Cancer | HER2-negative Metastatic Breast CancerGermany, Switzerland
Clinical Trials on Patritumab Deruxtecan
-
The Netherlands Cancer InstituteDaiichi Sankyo, Inc.Not yet recruitingEGFR Gene Mutation | Non-Small Cell Lung Carcinoma | Advanced Non-Small Cell Squamous Lung Cancer
-
SCRI Development Innovations, LLCDaiichi Sankyo, Inc.RecruitingMetastatic Breast Cancer | Locally Advanced Breast CancerUnited States
-
Daiichi SankyoMerck Sharp & Dohme LLCRecruitingMelanoma | Head and Neck Cancer | Gastric Cancer | Advanced Solid TumorJapan
-
Daiichi Sankyo, Inc.TerminatedMetastatic Colorectal CancerUnited States, Spain, Belgium, Japan, France, United Kingdom, Italy, Poland
-
Daiichi Sankyo, Inc.Active, not recruitingEGFR L858R | EGFR Exon 19 Deletion | Nonsquamous Non-small Cell Lung CancerKorea, Republic of, United States, Netherlands, Spain, United Kingdom, Japan, Austria, Belgium, Italy, France, Taiwan, Germany, Australia, Singapore, China, Hong Kong, Norway, Canada, Poland, Portugal, Switzerland
-
Daiichi SankyoDaiichi Sankyo Co., Ltd.Active, not recruitingNon-Small Cell Lung Cancer Metastatic | Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor ReceptorUnited States, Spain, Korea, Republic of, France, United Kingdom, Taiwan, Australia, Japan, China, Netherlands, Italy, Germany, Austria, Belgium, Bulgaria, Singapore
-
SOLTI Breast Cancer Research GroupDaiichi Sankyo, Inc.Active, not recruiting
-
Mustafa Khasraw, MBChB, MD, FRCP, FRACPDaiichi SankyoNot yet recruitingA Window of Opportunity Study of Patritumab Deruxtecan in Patients With Brain Metastases (PARAMETer)Brain Metastases, AdultUnited States
-
MedSIRDaiichi SankyoRecruitingMetastatic Breast Cancer | Solid Tumor, Adult | Advanced Non-Small Cell Squamous Lung CancerSpain, Austria
-
Gustave Roussy, Cancer Campus, Grand ParisDaiichi Sankyo, Inc.RecruitingMetastatic Breast CancerFrance